HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

pochoxime A

structure in first source

Also Known As:

NXD 30001; NXD-30001; NXD30001

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Oximes: 1292
      - pochoxime A: 3
- Lactones: 1549
  - pochoxime A: 3

Experts

1.	Chen, Ruihong: 2 articles (07/2013 - 09/2010)
2.	Jaffer, Zahara M: 2 articles (07/2013 - 09/2010)
3.	Rubenstein, Allan E: 2 articles (07/2013 - 09/2010)
4.	Chen, Hao: 1 article (01/2020)
5.	Cheng, Zhixiang: 1 article (01/2020)
6.	Gong, Yuanying: 1 article (01/2020)
7.	Ma, Yufang: 1 article (01/2020)
8.	Thompson, Reid C: 1 article (01/2020)
9.	Wang, Jialiang: 1 article (01/2020)
10.	Xue, Lixia: 1 article (01/2020)

Related Diseases

1.	Carcinogenesis 09/01/2010 - "Our findings establish that the Hsp90 inhibitor NXD30001 is a therapeutically multivalent molecule, whose actions strike GBM at the core of its drivers of tumorigenesis and represent a compelling rationale for its use in GBM treatment." 07/15/2013 - "The results showed that NXD30001 in NF2-deficient schwannoma suppressed multiple pathways necessary for tumorigenesis. "
2.	Neoplasms (Cancer) 01/01/2020 - "Radiotherapy solely increased median survival of tumor-bearing mice from 31 d to 38 d (P<0.05), while NXD30001 combined with radiation further extended survival to 43 d (P<0.05). " 01/01/2020 - "In a murine orthotopic model of human glioblastoma, NXD30001 marvelously induced tumor regression and extended median survival of tumor-bearing mice by approximately 20% when compared with the vehicle group (37 d vs 31 d, P<0.05). " 09/01/2010 - "The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme."
3.	Glioblastoma (Glioblastoma Multiforme) 01/01/2020 - "NXD30001 also increased radio-sensitivity in glioblastoma stem cells (GSCs) at suboptimal concentrations. " 01/01/2020 - "A Brain-Penetrating Hsp90 Inhibitor NXD30001 Inhibits Glioblastoma as a Monotherapy or in Combination With Radiation." 01/01/2020 - "In a murine orthotopic model of human glioblastoma, NXD30001 marvelously induced tumor regression and extended median survival of tumor-bearing mice by approximately 20% when compared with the vehicle group (37 d vs 31 d, P<0.05). " 09/01/2010 - "The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme."
4.	Neurilemmoma (Schwannoma) 07/15/2013 - "The results showed that NXD30001 in NF2-deficient schwannoma suppressed multiple pathways necessary for tumorigenesis. " 07/15/2013 - "The antiproliferative activity of NXD30001 was tested in NF2-deficient cell lines and in human primary schwannoma and meningioma cultures in vitro. "
5.	Meningioma (Meningiomas) 07/15/2013 - "The antiproliferative activity of NXD30001 was tested in NF2-deficient cell lines and in human primary schwannoma and meningioma cultures in vitro. "

Related Therapies and Procedures

1.	Radiotherapy